Health iQ Limited, Office 213, 23 Austin Friars, London, EC2N 2QP
Mon - Fri: 9:00AM - 17:00PM Sat - Sun: Closed
+ 44 (0)20 3542 5338
Welcome to MedicalPress a Premium Medical Theme
+44 (0) 20 3542 5338

COVID-19 Tracker: Why do we need this campaign now?

The health service’s response to COVID-19 has far-reaching consequences that are being felt across specialties and therapy areas.

In a bid to free-up critical care capacity, NHS England has recently published a set of guidelines that transform patient pathways and impact demand. They change how and where care is provided, reduce elective appointments and, in some cases, restrict the number of new patients able to access services.

In its role as partner to the UK’s health service, the life sciences industry has both a moral obligation and a business incentive to understand and respond to these changes proactively. Successfully doing so requires an intelligent approach.

At HealthIQ, we use data and analytics to help organizations understand and model how pathway changes may impact the way their products are supplied and deployed.

We can also help them identify new ways to work with healthcare teams in their joint quest to provide high quality care and improve outcomes in unprecedented times.

Uncover the unmet need created by COVID-19 with our bespoke specialty reports

No therapy area is homogenous. Each contains a wide range of people with differing risks, needs and potential outcomes.

Our rheumatology report is the first in a series of publications built using HealthIQ’s intelligent data analytics and modelling tools. It helps organisations unpick how COVID-19 and related pathway changes will impact on this particular patient group, both immediately and in the longer term.

It provides detailed analysis of:

  • Numbers of vulnerable and shielding patients, based on factors such as diagnosis and medication schedule
  • How changes in the quantity or frequency of new and follow-up consultations can impact on the specified patient group
  • Changes in patient demand for care by diagnosis code, medication utilised, and age profile using longitudinal data.
  • 2019 monthly inpatient and outpatient data as an indicator of potential unmet need

It will help life sciences companies working within rheumatology to:

  • Uncover where their products could help the NHS reduce or mitigate the impact of COVID-related changes on treatment and outcomes
  • Predict and support changes in the way their products are supplied and deployed (e.g. home care vs. hospital care)
  • Understand how pathway changes might impact the overall demand for their product

Follow your cohort longitudinally throughout the pandemic to understand their outcomes

 

COVID-19 is changing patient pathways overnight, having far-reaching consequences for specialist services and the people who rely on them. In order to respond to the unmet need created by this rapidly evolving crisis, organisations first need to identify and understand it.

Hospital Episode Statistics (HES) data is the foundation of this understanding, yet its longitudinal analysis has traditionally been lengthy, laborious and complex.

Cohort Builder, HealthIQ’s new longitudinal analysis tool, changes all that. It enables the user to select a specific patient cohort and then quickly pull data from multiple HES datasets into one integrated dashboard for analysis.

It will help life sciences companies working within rheumatology to:

  • Access longitudinal data rapidly in many different specialties, often within minutes
  • Refine their own criteria for outcome measurement, rather than use predefined one
  • Track cohorts of patients over time. Our data allows cohorts to be followed before the and through the pandemic see their journey, and what outcomes result from their care pathway, medication and care package.
  • Analyse unlimited specialty areas and diagnosis codes
  • Analyse demand down to individual trust level
  • Access monthly aggregate and trust level HES data, updated every monthIn short, it puts the information that companies need to spot opportunities for improvement, drive business change and protect the NHS at users’ fingertips.

Accurately model the financial and clinical cost of Covid-19

In an evolving crisis like COVID-19, simulation models that use up-to-date information are essential to predicting the impact of pathway and intervention changes on product demand.

Our data-driven COVID-19 model enables organisations to do just that. It is a proactive approach that puts companies in control of the uncertainties surrounding demand, clinical outcomes, and revenue changes.

By accurately modelling the changes set out in the new NHS England COVID-19 management guidelines, organisations can:

  • Reveal how changes such as greater utilization of homecare and moving non-elective appointments to telemedicine creates need for their products
  • Model varying pandemic lengths, second wave scenarios, and possible “return to normal” timescales to overcome uncertainty
  • Forecast revenues by modelling how changes to new and follow up outpatient appointments and elective procedures impact demand and patient backlog
  • Model the impact of pathway and demand changes on market share, as well as the financial impact of supporting Trusts in need, both on the NHS and life-science companies.
  • Test new models of care and changes to care pathways to support the NHS

Conclusion

There is no doubt that the changes to NHS resource allocation necessitated by the Covid-19 pandemic will have implications across all specialties and therapy areas. That impact will continue for many months to come.

By moving to proactively address this, the Life Sciences industry can identify opportunities to help the NHS mitigate the impact on patient care and understand the changes in products demand.

To do this effectively, organisations need a firm understanding of how the re-structuring of pathways is likely to affect specific cohorts of patients within their key therapy areas.

Mounting an effective response rests on the ability to understand the pre-crisis situation, model the likely impacts of varying scenarios, and track the rapidly evolving, real-world situation.

HealthIQ has developed a suite of materials to assist organisations in their quest to protect patient outcomes and business objectives.

The first of a series of reports analyzing the pre-COVID landscape in a range of therapy areas is now available, and we have launched a cutting edge longitudinal analysis tool, Cohort Builder, which enables companies to build and track their own specific cohorts.

We have also released the COVID-19 modelling tool, enabling companies to accurately forecast the likely impact of changing pathways on product demand, as well as assess the results of interventions proposed to reduce the buildup of service backlog during the crisis.

No Comments
Post a Comment
Name
E-mail
Website